IMCR — Immunocore Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $1.56bn
- $1.09bn
- $400.02m
Annual cashflow statement for Immunocore Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -180 | -52.5 | -55.3 | -51.1 | -35.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 51.3 | 22.2 | 48.4 | 27.8 | 16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -22 | -24.2 | 5.78 | 45.1 | -9.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -143 | -49.2 | 2.94 | 26.1 | -10.7 |
| Capital Expenditures | -1.39 | -2.2 | -5.42 | -5.17 | -4.34 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.106 | 0.006 | 0 | -350 | -12 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.28 | -2.2 | -5.42 | -355 | -16.3 |
| Financing Cash Flow Items | — | -1.77 | 0 | -13.4 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 288 | 145 | 34.3 | 344 | 12.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 144 | 81.4 | 40.2 | 13.1 | 12 |